Form 8-K
8-K — OptimizeRx Corp
Accession: 0001213900-26-041604
Filed: 2026-04-09
Period: 2026-04-03
CIK: 0001448431
SIC: 7389 (SERVICES-BUSINESS SERVICES, NEC)
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — ea0285473-8k_optimize.htm (Primary)
EX-99.1 — PRESS RELEASE, DATED APRIL 8, 2026 (ea028547301ex99-1.htm)
GRAPHIC (ea028547301_ex99-1img1.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — CURRENT REPORT
8-K (Primary)
Filename: ea0285473-8k_optimize.htm · Sequence: 1
false
0001448431
0001448431
2026-04-03
2026-04-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April
3, 2026
OptimizeRx Corporation
(Exact name of registrant as specified in charter)
Nevada
001-38543
26-1265381
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
260 Charles Street, Suite 302
Waltham, MA 02453
(Address of principal executive offices)
Registrant’s telephone number, including
area code: 248.651.6568
Not
Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 Par Value
OPRX
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On April 3, 2026, the Board of Directors (the “Board”)
of OptimizeRx Corporation (the “Company”), upon the recommendation of the Board’s Nominating & Governance Committee,
appointed Mary Varghese Presti to serve as a director of the Company until the date of the Company’s 2026 annual meeting of stockholders
and until her successor is elected and qualified, except in the event of her earlier death, resignation or removal. The appointment of
Ms. Varghese Presti as an independent director is in furtherance of the Company’s ongoing process to refresh and expand its Board.
In connection with Ms. Varghese Presti’s appointment to the Board, the Board expanded the size of the Board to seven members from
its current six members. The Board also appointed Ms. Varghese Presti to serve as a member of the Audit Committee.
As a non-employee director, Ms. Varghese Presti will participate in
the Company’s previously disclosed non-employee director compensation program, which includes, among other things, an annual cash
retainer of $45,000, an annual equity grant with a grant date value of approximately $175,000, and an additional annual cash retainer
of $10,000 for serving as a member of the Audit Committee.
Item 7.01 Regulation FD Disclosure.
On April 8, 2026, the Company issued a press release announcing the
appointment of Ms. Varghese Presti to its Board. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit
99.1 and is incorporated herein by reference.
The information in this Item 7.01 and Exhibit 99.1 attached hereto
is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in such filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit Number
Description
99.1
Press release, dated April 8, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OPTIMIZERX CORPORATION
Date: April 8, 2026
By:
/s/ Marion Odence-Ford
Name:
Marion Odence-Ford
Title:
Chief Legal & Administrative Officer
2
EX-99.1 — PRESS RELEASE, DATED APRIL 8, 2026
EX-99.1
Filename: ea028547301ex99-1.htm · Sequence: 2
Exhibit 99.1
OptimizeRx Appoints Mary Varghese Presti
to Board of Directors
Microsoft Health & Life Sciences COO brings
expertise in scaling healthcare platforms, commercializing new technologies, and driving operational efficiency
WALTHAM, MA – April 8, 2026 (GLOBE NEWSWIRE)
– OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences
companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Mary Varghese Presti to its
Board of Directors. The appointment of Varghese Presti as an independent director is in furtherance of the Company’s ongoing process
to refresh and expand its Board of Directors.
Varghese Presti brings more than 25 years of experience
at the intersection of healthcare, life sciences, and technology, with a track record of building and scaling platforms that translate
innovation into real-world impact. She currently serves as Corporate Vice President and Chief Operating Officer of Microsoft’s Health
& Life Sciences organization, where she leads operational strategy and execution for a global, high-growth business.
At Microsoft, Varghese Presti plays a central
role in advancing the company’s healthcare strategy during a period of rapid transformation driven by AI. She has helped operationalize
next-generation, AI-powered capabilities, including clinical and agentic technologies, that are reshaping how care is delivered, how workflows
are managed, and how health systems scale. Her work focuses on enabling healthcare organizations to increase clinical capacity, improve
decision-making, and deliver more connected, data-driven care.
Varghese Presti has held leadership roles across
some of the most influential organizations in healthcare and technology, including Microsoft, Nuance, IBM Watson Health, athenahealth,
and Pfizer. Her career uniquely spans care delivery, health policy, life sciences, and enterprise
technology, giving her a cross-sector perspective on how innovation moves from concept to adoption at scale.
She brings deep experience across the M&A
lifecycle, including strategic diligence, post-acquisition integration, and portfolio scaling. At Microsoft, she has been closely involved
in integration efforts following the acquisition of Nuance, helping align product, operational, and commercial capabilities to scale the
combined platform. Previously, at IBM Watson Health, she led a life sciences portfolio built through multiple acquisitions and played
a key role in diligence efforts related to IBM’s divestiture of Watson Health to private equity ownership.
Across these roles, she has consistently led efforts
to modernize product portfolios, build new businesses, and drive operational and commercial transformation in complex, regulated environments.
“Mary’s experience from deal strategy
through post transaction integration, scaling platforms, commercializing innovation, and driving operational rigor at some of the world’s
leading healthcare and technology companies aligns directly with our strategy,” said Steve Silvestro, Chief Executive Officer of
OptimizeRx. “As we continue to evolve OptimizeRx into a more integrated, product-led platform with increasing recurring and subscription-based
revenue, her perspective will be critical in helping us accelerate growth, expand our product portfolio, and deliver long-term shareholder
value.”
“I’m excited to join OptimizeRx at
a time when both healthcare and technology are evolving so quickly,” said Varghese Presti. “There is real opportunity to rethink
how data, engagement, and intelligences come together to better support clinicians and patients. I look forward to working with the Board
and leadership team to help scale the platform and build solutions that deliver meaningful impact across the healthcare ecosystem.”
Varghese Presti began her career as a pediatric
nurse at Johns Hopkins, an experience that continues to shape her approach to healthcare innovation,
grounded in the realities of care delivery and the importance of maintaining the human connection at the center of care.
About OptimizeRx
OptimizeRx is a leading healthcare technology
company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative
artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT)
to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create
synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Our commitment to privacy-safe, patient-centric
technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients
at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical
and life sciences companies to transform the healthcare landscape and create a healthier future for all.
For more information, follow the Company on X,
LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward-Looking
Statements
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”,
“estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”,
“targets", “designed”, “could”, “may”, “should”, “will” or other
similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect
the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact,
are forward-looking statements, including, without limitation, statements relating to OptimizeRx’s appointment of a new Board member,
and the Company’s plans to scale platforms, commercialize innovation, and drive operational rigor, to evolve into a more integrated,
product-led platform with increasing recurring and subscription-based revenue, to accelerate growth, expand its product portfolio, and
deliver long-term shareholder value, and to build solutions that deliver meaningful impact across the healthcare ecosystem. Because such
statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking
statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding
the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking
statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the
timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties
including, but not limited to, the Company’s success with the appointment of a new Board member, the effect of government regulation,
seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to
keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic
health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2025, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance
on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to
update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may
be required by law.
OptimizeRx Investor Relations Contact
Andy D’Silva, Chief Business Officer
adsilva@optimizerx.com
OptimizeRx Marketing Contact
Jennifer Dinkel, VP, Marketing
jdinkel@optimizerx.com
Press Inquiries
Matter Communications
optimizerx@matternow.com
GRAPHIC
GRAPHIC
Filename: ea028547301_ex99-1img1.jpg · Sequence: 3
Binary file (4853 bytes)
Download ea028547301_ex99-1img1.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Cover
Apr. 03, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Apr. 03, 2026
Entity File Number
001-38543
Entity Registrant Name
OptimizeRx Corporation
Entity Central Index Key
0001448431
Entity Tax Identification Number
26-1265381
Entity Incorporation, State or Country Code
NV
Entity Address, Address Line One
260 Charles Street
Entity Address, Address Line Two
Suite 302
Entity Address, City or Town
Waltham
Entity Address, State or Province
MA
Entity Address, Postal Zip Code
02453
City Area Code
248
Local Phone Number
651.6568
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, $0.001 Par Value
Trading Symbol
OPRX
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration